承業生醫投資控股股份有限公司 2025 Sustainability Report

Report summary

• This page summarizes the 2025 sustainability report and ESG report PDF source for 承業生醫投資控股股份有限公司 (4164).
• The reporting period is 2025/01/01 to 2025/12/31, in the 生技醫療業 industry.
• third-party verification or assurance body information is not currently provided; this can be used to review report verification, assurance, and disclosure standards.
• Compare public disclosure approaches across prior-year and peer reports. Your company’s actual disclosures must still be based on its own data and supporting evidence.

Report details

Company

承業生醫投資控股股份有限公司（4164）

Reporting Year

2025

Disclosure Period

2025/01/01 to 2025/12/31

Industry

生技醫療業

Third-party information

third-party verification or assurance body information is not currently provided

PDF source

The original ESG report PDF can be downloaded or opened from this page

2025 ESG Metrics and Industry Comparison

Greenhouse Gas Emissions

Scope 1 Emissions (Tons CO2e)

841

Reporting Boundary：已完成合併財務報表之母子公司

Verification：否

Scope 2 Emissions (Tons CO2e)

1,096

Reporting Boundary：已完成合併財務報表之母子公司

Verification：否

Scope 3 Emissions (Tons CO2e)

1,029

Reporting Boundary：已完成合併財務報表之母子公司

Verification：否

Energy Management

Renewable Energy Share

0%

Reporting Boundary：包含合併財務報之母子公司

Verification：Not disclosed

Ranked 10 among 15 companies in the same industry (percentile 0).

Water Management

Water Use (Metric Tons)

10,943

Reporting Boundary：包含合併財務報之母子公司

Verification：Not disclosed

Board of Directors

Board Seats (Including Independent Directors)

7

Independent Director Seats

3

Female Director Ratio

14.3%

Ranked 40 among 61 companies in the same industry (percentile 22).

Board Meeting Attendance Rate

100%

Ranked 1 among 61 companies in the same industry (percentile 75).

Independent Director Ratio

42.9%

Ranked 25 among 61 companies in the same industry (percentile 42).

Source: Taiwan Stock Exchange / Taipei Exchange, Corporate ESG Disclosure Summary (2025), under the Open Government Data License, version 1.0. Open Government Data License, Version 1.0

How to use this report

• Compare how 承業生醫投資控股股份有限公司 structured 生技醫療業 sustainability report chapters and material topics in 2025.
• Confirm the reporting period, third-party verification or assurance information, and downloadable ESG report PDF source.
• Mark public disclosures and original page numbers that can be referenced as research materials for planning chapters and indicators for your own company.